ℹ️ Compiled from public regulatory records · Last regulator revision: December 23, 2025

Pyridostigmine

Anticholinesterases

US FDAGB MHRA

Drug class: Anticholinesterases
Availability: Prescription only
Routes: Oral
Markets covered: 2
Products on record: 8

N07AAAnticholinesterases

Overview

Plain-language summary, compiled from the cited regulatory records

Pyridostigmine is an anticholinesterase medication [1]. It is used to treat myasthenia gravis [1]. Myasthenia gravis is a condition that causes weakness in the voluntary muscles [1].

Pyridostigmine is available in tablet form [1]. It works by increasing the levels of a chemical messenger in the muscles, which helps to improve muscle strength and reduce fatigue [1]. This medication is part of the anticholinesterase drug class [1].

This active ingredient is sold under several brand names [1]. There were no adverse event reports for this ingredient in the last 12 months [2].

This is not medical advice. Consult a qualified healthcare professional.

Regulatory status by market

Market	Regulator	Products	Last revision
US United States	FDA	4	December 23, 2025
GB United Kingdom	MHRA	4	November 10, 2025

USUnited States· FDA

4 products

Uses

USOfficial regulatory label· revised August 4, 2025[1]

INDICATIONS AND USAGE
Pyridostigmine Bromide Tablets USP are useful in the treatment of myasthenia gravis.

How to take

GBUnited Kingdom· MHRA

4 products

Uses

GBOfficial regulatory label· revised February 14, 2025[2]

Myasthenia gravis, paralytic ileus and post-operative urinary retention.

How to take

GBOfficial regulatory label

Drug interactions

Known interactions involving Pyridostigmine. Select one for details. This list is informational and not a complete interaction checker.

Siponimod Alectinib Amifampridine Amikacin Atropine Betamethasone Bethanechol Biperiden Brigatinib Budesonide Clidinium Clozapine Corticotropin Cosyntropin Crizotinib Darifenacin Deflazacort Dexamethasone Dicyclomine Disopyramide Donepezil Edrophonium Fingolimod Flavoxate Fludrocortisone Galantamine Gentamicin Glycopyrronium Homatropine Hydrocortisone Hyoscyamine Ivabradine Kanamycin Lasmiditan Mepenzolate Methscopolamine Methylprednisolone Neomycin Neostigmine Netilmicin Oxybutynin Ozanimod Paromomycin Physostigmine Plazomicin Prednisolone Prednisone Procainamide Procyclidine Propantheline Quinidine Rivastigmine Scopolamine Solifenacin Streptomycin Succinylcholine Tacrine Thalidomide Tobramycin Tolterodine Triamcinolone Trihexyphenidyl Trospium Acetaminophen Albuterol Alendronate Allopurinol Amlodipine Aspirin Atorvastatin Azathioprine Carbamazepine Carvedilol Ceftriaxone Celecoxib Cetirizine Citalopram Clonazepam Clopidogrel Cyclosporine Diazepam Diclofenac Digoxin Diltiazem Duloxetine Enalapril Erythromycin Estradiol Ezetimibe Famotidine Fentanyl Fexofenadine Finasteride Furosemide Gabapentin Heparin Ibuprofen Irbesartan Lactulose Lansoprazole Levothyroxine Lisinopril Lorazepam Losartan Lovastatin Meloxicam Metformin Methotrexate Metoprolol Minocycline Mirtazapine Montelukast Morphine Moxifloxacin Naproxen Nystatin Ofloxacin Omeprazole Ondansetron Pantoprazole Paroxetine Pioglitazone Potassium Chloride Pravastatin Pregabalin Quetiapine Rabeprazole Ramipril Ranitidine Risedronic Acid Rofecoxib Rosuvastatin Salmeterol Sevelamer Simvastatin Spironolactone Tacrolimus Telithromycin Tiotropium Topiramate Torsemide Valsartan Verapamil Warfarin Zoledronic Acid Zolpidem Zopiclone

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]FDA DailyMed · 0a114d99-e50b-49… · revised August 4, 2025 [PDF]
[2]MHRA (UK) · PL136210081 · revised February 14, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.